A BILL 
To amend the Biologics Price Competition and Innovation 
Act of 2009 to make improvements with respect to the 
transition of biological products, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. STREAMLINING THE TRANSITION OF BIOLOGI-
3
CAL PRODUCTS. 
4
(a) CONTINUED REVIEW
OF CERTAIN APPLICA-
5
TIONS.—Section 7002(e)(4)(B) of the Biologics Price 
6
Competition and Innovation Act of 2009 (Public Law 
7
111–148) is amended— 
8
(1) by striking clauses (i), (ii), and (vi); and 
9
02:54 Mar 14, 2020
H6155
2 
•HR 6155 IH
(2) by inserting before clause (iii) the following: 
1
‘‘(i) IN GENERAL.—With respect to an 
2
application for a biological product sub-
3
mitted under subsection (b) or (j) of sec-
4
tion 505 of the Federal Food, Drug, and 
5
Cosmetic Act (21 U.S.C. 355) that is filed 
6
not later than March 23, 2019, and that is 
7
pending (or tentatively approved) as of 
8
March 23, 2020— 
9
‘‘(I) the Secretary shall continue 
10
to review such application under such 
11
section 505, even if such review con-
12
tinues after March 23, 2020; and 
13
‘‘(II) upon approval of such ap-
14
plication, such application shall be 
15
deemed to be a license for the biologi-
16
cal product under section 351 of the 
17
Public Health Service Act, pursuant 
18
to subparagraph (A), and any period 
19
of exclusivity, as applicable, shall be 
20
determined in accordance with such 
21
section. 
22
‘‘(ii) 
TREATMENT
OF
LISTED 
23
DRUGS.—With respect to a drug that is a 
24
biological product that has been deemed li-
25
02:54 Mar 14, 2020
H6155
3 
•HR 6155 IH
censed under section 351 of the Public 
1
Health Service Act (42 U.S.C. 262) pursu-
2
ant to subparagraph (A) and that is ref-
3
erenced in an application described in 
4
clause (i), such drug shall— 
5
‘‘(I) continue to be identified as a 
6
listed drug on the list published pur-
7
suant to section 505(j)(7) of the Fed-
8
eral Food, Drug, and Cosmetic Act, 
9
and the information for such drug on 
10
such list shall not be revised (or re-
11
moved) unless and until the date on 
12
which each application described in 
13
clause (i) that references such drug 
14
is— 
15
‘‘(aa) no longer pending re-
16
view (or the approval of such 
17
drug is tentative) under section 
18
505 of the Federal Food, Drug, 
19
and Cosmetic Act (21 U.S.C. 
20
355); or 
21
‘‘(bb) removed from such list 
22
in accordance with subparagraph 
23
(C) of such section 505(j)(7); 
24
02:54 Mar 14, 2020
H6155
4 
•HR 6155 IH
‘‘(II) be subject only to require-
1
ments applicable to biological products 
2
licensed under section 351 of the Pub-
3
lic Health Service Act (42 U.S.C. 
4
262); and 
5
‘‘(III) be deemed to be a ref-
6
erence product under such section 351 
7
on the date on which the last applica-
8
tion described in clause (i) that ref-
9
erences such drug is no longer pend-
10
ing review (or tentatively approved) 
11
under section 505 of the Federal 
12
Food, Drug, and Cosmetic Act (21 
13
U.S.C. 355).’’. 
14
(b) CERTAIN INSULIN PRODUCTS DEEMED INTER-
15
CHANGEABLE BIOSIMILARS.—Section 7002(e)(4) of the 
16
Biologics Price Competition and Innovation Act of 2009 
17
(Public Law 111–148) is amended by adding at the end 
18
the following: 
19
‘‘(C) 
CERTAIN
INSULIN
PRODUCTS 
20
DEEMED INTERCHANGEABLE BIOSIMILARS.— 
21
‘‘(i) IN
GENERAL.—In carrying out 
22
subparagraph (A), a covered insulin prod-
23
uct shall be deemed to be an interchange-
24
able biosimilar biological product licensed 
25
02:54 Mar 14, 2020
H6155
5 
•HR 6155 IH
under section 351(k) of the Public Health 
1
Service Act. 
2
‘‘(ii) DEFINITIONS.—In this subpara-
3
graph: 
4
‘‘(I) The terms ‘biosimilar’ and 
5
‘interchangeable’ have the meaning 
6
given such terms in section 351(i) of 
7
the Public Health Service Act. 
8
‘‘(II) The term ‘covered insulin 
9
product’ means a biological product 
10
(including a chemically synthesized 
11
polypeptide) that is— 
12
‘‘(aa) an insulin product; 
13
and 
14
‘‘(bb) approved under sec-
15
tion 505 of the Federal Food, 
16
Drug, and Cosmetic Act pursu-
17
ant to an application submitted 
18
under subsection (b)(2) of such 
19
section.’’. 
20
Æ 
02:54 Mar 14, 2020
H6155
